Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Publication year range
1.
Int Ophthalmol ; 44(1): 99, 2024 Feb 20.
Article in English | MEDLINE | ID: mdl-38376602

ABSTRACT

PURPOSE: To assess the prevalence of autoimmune diseases (ADs) associated with ocular cicatricial pemphigoid (OCP) and analyze clinical, laboratory, and treatment associations between these entities. METHODS: A multicentre cross-sectional study of patients with an OCP diagnosis. The population was divided into two groups according to their association with other ADs or not. Clinical, laboratory and treatment variables were described and compared between groups. A multivariable logistic regression analysis was performed to identify variables that could suggest the association between OCP and ADs. RESULTS: Eighty-eight patients were recruited, with a mean age at diagnosis of 64.3 years (SD 11.9). Biopsy was performed in 86.8% of the patients. There was a median delay of 2 years from the onset of symptoms to diagnosis. Extraocular involvement was evidenced in 11.5%. The group associated with ADs included 24 patients (27.3%). The most prevalent diagnosis was Sjögren´s syndrome. Hypergammaglobulinemia was associated with ADs and OCP, adjusted for age, sex, smoking, skin and mucosal involvement, and erythrocyte sedimentation rate (OR 8.7; 95%CI 1.6-46.8; p = 0.012). CONCLUSIONS: Due to OCP's autoimmune nature, it could coexist with other ADs. This study observed that more than a quarter of the population presented with this association, and hypergammaglobulinemia could suggest it.


Subject(s)
Autoimmune Diseases , Pemphigoid, Benign Mucous Membrane , Sjogren's Syndrome , Humans , Middle Aged , Pemphigoid, Benign Mucous Membrane/complications , Pemphigoid, Benign Mucous Membrane/diagnosis , Cross-Sectional Studies , Hypergammaglobulinemia , Autoimmune Diseases/complications , Autoimmune Diseases/diagnosis , Autoimmune Diseases/epidemiology
4.
Rev. colomb. reumatol ; 29(1): 57-67, Jan.-Mar. 2022. tab, graf
Article in English | LILACS | ID: biblio-1423904

ABSTRACT

ABSTRACT Ocular cicatricial pemphigoid (OCP) is a chronic, immune-mediated, bullous, cicatricial disease within the spectrum of mucocutaneous membranous pemphigoids (MMP). Although the diagnosis is often ophthalmological, due to the autoimmune nature of the pathology, it requires a joint approach with rheumatologists and immunologists. The objective of this narrative review was to explore the evidence available in the literature from 2000 to 2020 with respect to clinical manifestations, diagnosis, and treatment. The clinical presentation varies widely, from mild cases with slow progression of years of progression, to severe cases with a torpid and rapidly progressive evolution to fibrosis, refractory to multiple treatments. A com plete evaluation of the patient will help guide the diagnosis. The gold standard for diagnosis is conjunctival biopsy with direct immunofluorescence, although on occasions it can be reached if the symptoms are characteristic. Treatment is local and systemic according to its severity and evolution. The evidence on topical and systemic therapeutics is obtained mainly from uncontrolled observational and experimental studies. Immunomodulatory therapy has made it possible to preserve vision and, in many cases, prevent sequelae. The evolu tion is linked to the early diagnosis and immunosuppressive treatment, so it is essential to be aware of this disease, the diagnostic methods, as well as the immunomodulating and immunosuppressive therapies available.


RESUMEN El penfigoide ocular cicatrizal (POC) es una enfermedad crónica, inmunomediada ampollar, mucosinequiante, comprendida dentro del espectro de penfigoides membranosos mucocutáneos (PMM). El diagnóstico es, con frecuencia, oftalmológico, pero debido al carácter autoinmune de la patología, requiere el abordaje en conjunto con reumatólogos e inmunólogos. El objetivo de esta revisión narrativa fue explorar la evidencia disponible en la literatura, desde el año 2000 hasta el 2020, en lo que respecta a sus manifestaciones clínicas, diagnóstico y tratamiento. La presentación clínica varía ampliamente, desde casos leves con progresión lenta de años de evolución hasta casos severos con evolución tórpida y rápidamente progresiva a la fibrosis, refractarios a múltiples tratamientos. Una evaluación completa del paciente ayudará a guiar el diagnóstico. El estándar de oro diagnóstico es la biopsia conjuntival con inmunofluorescencia directa, si bien en ocasiones puede diagnosticarse por la clínica característica. El tratamiento es local y sistêmico de acuerdo con su severidad y evolución. En los últimos 20 anos, la evidencia sobre los tratamientos tópicos y sistêmicos corresponde en su mayoría a estudios observacionales y experimentales no controlados. Los métodos de tratamiento inmunomoduladores han permitido preservar la visión y, en muchos casos, prevenir secuelas. La evolución está ligada al diagnóstico temprano y a los tratamientos disponibles, por lo que es fundamental el conocimiento de esta patología, los métodos diagnósticos y los tratamientos inmunomoduladores e inmunosupresores.


Subject(s)
Male , Female , Middle Aged , Dry Eye Syndromes , Pemphigoid, Benign Mucous Membrane , Conjunctival Diseases , Eye Diseases
5.
Dermatol. argent ; 5(5): 390-2, oct.-nov. 1999. ilus
Article in Spanish | LILACS | ID: lil-254858

ABSTRACT

Se presenta el caso de una paciente de sexo femenino, de 11 años de edad, con diagnóstico de dermatomiositis y morfea. Se destaca la escasa frecuencia de dicha asociación y la respuesta faborable al tratamiento con corticoides sistémicos. Se efectúa una revisión del tema en la literatura


Subject(s)
Humans , Female , Dermatomyositis/diagnosis , Scleroderma, Localized/diagnosis , Adrenal Cortex Hormones/therapeutic use , Scleroderma, Localized/pathology
6.
Dermatol. argent ; 5(5): 390-2, oct.-nov. 1999. ilus
Article in Spanish | BINACIS | ID: bin-13367

ABSTRACT

Se presenta el caso de una paciente de sexo femenino, de 11 años de edad, con diagnóstico de dermatomiositis y morfea. Se destaca la escasa frecuencia de dicha asociación y la respuesta faborable al tratamiento con corticoides sistémicos. Se efectúa una revisión del tema en la literatura (AU)


Subject(s)
Humans , Female , Dermatomyositis/diagnosis , Scleroderma, Localized/diagnosis , Scleroderma, Localized/pathology , Adrenal Cortex Hormones/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...